Best Paper Award

Thank you for your continuous support. We regret to inform you that the deadline for announcing the winner of the 2022 Best Paper Award has been postponed until the end of October 2024.

The Editorial Office would like to apologize for any inconvenience caused. If you have any questions, please do not hesitate to contact us.


Dear Colleagues,

We are pleased to announce the “COVID 2022 Best Paper Award” for research and review articles published in COVID from 01 January 2022 to 31 December 2022. One review and one research article will receive an award each. The papers will be selected after a thorough evaluation by the journal Award Committee led by the Editor-in-Chief, Prof. Dr. Giuseppe Novelli.

Eligibility for the Award:
– Papers published in COVID from 01 January 2022 to 31 December 2022;
– Open to all career levels;
– Both regular and Special Issue submissions will be considered.

Selection Criteria:
The papers will be selected by the journal Award Committee according to the following criteria:
– Scientific merit and broad impact;
– Originality of the research objectives and/or the ideas presented;
– Creativity of the study design or uniqueness of the approaches and concepts;
– Clarity of presentation;
– Citations and downloads.

The Prize:
– One review award: CHF 500 and a chance to publish a paper free of charge in COVID in 2024 after peer review;
– One research article award: CHF 500 and a chance to publish a paper free of charge in COVID in 2024 after peer review;
– Each winner will also receive a certificate.

The winners will be announced on the journal website in June 2024.

Kind regards,
COVID Editorial Office

 
COVID Best Paper Award
 

Eligibility and Requirements

– All papers published in COVID will be eligible (Both regular and Special Issue submissions).
 
Past Winners
 
Year: 

Winner

16 pages, 335 KiB  
Article
Public Health Resources, Religion, and Freedom as Predictors of COVID-19 Vaccination Rates: A Global Study of 89 Countries
by Shadi Omidvar Tehrani and Douglas D. Perkins
COVID 2022, 2(6), 703-718; https://doi.org/10.3390/covid2060053 - 30 May 2022
20 pages, 462 KiB  
Review
Risk/Benefit Profiles of Currently Approved Oral Antivirals for Treatment of COVID-19: Similarities and Differences
by Suzana Corritori, Nikolay Savchuk and C. David Pauza
COVID 2022, 2(8), 1057-1076; https://doi.org/10.3390/covid2080078 - 28 Jul 2022
Back to TopTop